Laidlaw & Co. Maintains Buy on Affimed, Raises Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Laidlaw & Co. analyst Yale Jen maintains a Buy rating on Affimed (NASDAQ:AFMD) and raises the price target from $15 to $25.
June 13, 2024 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Laidlaw & Co. analyst Yale Jen maintains a Buy rating on Affimed and raises the price target from $15 to $25.
The raised price target from $15 to $25 by Laidlaw & Co. indicates strong confidence in Affimed's future performance, likely leading to positive investor sentiment and a potential short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100